These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15909258)

  • 1. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska.
    Walker FJ; Singleton RJ; Bulkow LR; Strikas RA; Butler JC
    Clin Infect Dis; 2005 Jun; 40(12):1730-5. PubMed ID: 15909258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population.
    Jackson LA; Nelson JC; Whitney CG; Neuzil KM; Benson P; Malais D; Baggs J; Mullooly J; Black S; Shay DK
    Vaccine; 2006 Jan; 24(2):151-6. PubMed ID: 16122845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
    Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
    Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.
    Bliss SJ; Larzalere-Hinton F; Lacapa R; Eagle KR; Frizzell F; Parkinson A; Reid R; Craig M; Santosham M; O'Brien KL
    Arch Intern Med; 2008 Apr; 168(7):749-55. PubMed ID: 18413558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
    Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
    Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Whitney CG; Starkovich P; Dunstan M; Yu O; Nelson JC; Feikin DR; Shay DK; Baggs J; Carste B; Nahm MH; Carlone G
    Vaccine; 2005 May; 23(28):3697-703. PubMed ID: 15882530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries?
    Snow R; Babish JD; McBean AM
    Public Health Rep; 1995; 110(6):720-5. PubMed ID: 8570826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
    Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Nahm MH; Whitney CG; Yu O; Nelson JC; Starkovich PT; Dunstan M; Carste B; Shay DK; Baggs J; Carlone GM
    Vaccine; 2007 May; 25(20):4029-37. PubMed ID: 17391816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
    Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S
    Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(13):343-4. PubMed ID: 18385642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.
    Balmer P; Borrow R; Arkwright PD
    Vaccine; 2007 Aug; 25(34):6321-5. PubMed ID: 17629373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.